Cheryl Madson, MD
Family Medicine · Council Bluffs, IANPI 1821053406
Payments from drug & device makers
Across 224 payments — averaging $14.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$413
- AbbVie$403
- Amgen$321
- AstraZeneca$229
- Boehringer Ingelheim$212
- Lilly USA, LLC$184
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,190100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $413 |
| AbbVie(2 entities) | 26 | $403 |
| Amgen | 25 | $321 |
| AstraZeneca | 9 | $229 |
| Boehringer Ingelheim | 21 | $212 |
| Lilly USA, LLC | 22 | $184 |
| Novartis | 13 | $153 |
| Pfizer | 14 | $148 |
| Astellas Pharma US Inc | 10 | $137 |
| Boston Scientific | 2 | $136 |
| Sanofi-aventis U.S. LLC | 2 | $132 |
| Kowa Pharmaceuticals America, Inc. | 6 | $70 |
| Bayer | 5 | $70 |
| Amarin Pharma, Inc. | 5 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $64 |
| Abbott | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 4 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $50 |
| Ironwood Pharmaceuticals, Inc | 2 | $41 |
| Insulet Corporation | 1 | $37 |
| Johnson & Johnson | 3 | $36 |
| E.r. Squibb & Sons, L.L.C. | 3 | $33 |
| Sanofi Pasteur Inc. | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Scilex Pharmaceuticals Inc. | 2 | $26 |
| Merck | 2 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,190 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 216 | $203,315 |
| EliquisApixaban | 190 | $129,411 |
| KerendiaFinerenone | 111 | $104,218 |
| OzempicSemaglutide | 84 | $99,254 |
| JardianceEmpagliflozin | 85 | $96,637 |
| MounjaroTirzepatide | 77 | $88,790 |
| TrulicityDulaglutide | 84 | $88,086 |
| XareltoRivaroxaban | 119 | $69,410 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $40,811 |
| JanuviaSitagliptin Phosphate | 36 | $36,874 |
| MyrbetriqMirabegron | 63 | $29,366 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $24,976 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $23,552 |
| LinzessLinaclotide | 31 | $21,661 |
| Potassium Chloride | 339 | $7,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Symbicort | $229 | $206,381227 claims |
| Lilly USA, LLCMounjaro, Trulicity | $184 | $176,876161 claims |
| PfizerEliquis | $148 | $129,411190 claims |
| BayerKerendia | $70 | $104,218111 claims |
| Novo NordiskOzempic | $413 | $99,25484 claims |
| Boehringer IngelheimJardiance | $212 | $96,63785 claims |
| Johnson & JohnsonXarelto | $36 | $69,410119 claims |
| MerckJanuvia | $23 | $36,87436 claims |
| Astellas Pharma US IncMyrbetriq | $137 | $29,36663 claims |
| AbbVieLinzess, Synthroid | $403 | $26,05199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.
Other family medicine in Council Bluffs
- Jennifer KayCouncil Bluffs$613K
- Kevin SheppardCouncil Bluffs$20K
- Kavish RohatgiCouncil Bluffs$14K
- Mel RocaCouncil Bluffs$13K
- Joseph WanzekCouncil Bluffs$13K
- James WhalenCouncil Bluffs$12K
- Barclay MonasterCouncil Bluffs$10K
- Krista HillCouncil Bluffs$8K
- Jamie ArmbrusterCouncil Bluffs$7K
- Nicholas GoetschWaterloo$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.